Related Experiment Videos
CYP2D6*4 polymorphism is associated with statin-induced muscle effects.
Tony N Frudakis1, Matthew J Thomas, Siva N Ginjupalli
1DNAPrint genomics, Inc., Sarasota, FL 34236, USA. tfrudakis@dnaprint.com
Pharmacogenetics and Genomics
|August 19, 2007
Summary
The CYP2D6*4 genetic variant is linked to statin-induced muscle problems, including pain and elevated creatine kinase. This finding may help predict and prevent adverse drug reactions in patients taking statins.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Genetics
Background:
- Statin medications are widely prescribed for cardiovascular disease prevention.
- Statin use can lead to muscle-related adverse events, ranging from mild myalgia to severe rhabdomyolysis.
- Understanding genetic predispositions to statin-induced muscle symptoms is crucial for personalized medicine.
Purpose of the Study:
- To investigate the association between common single nucleotide polymorphisms (SNPs) and atorvastatin-induced muscle events.
- To identify genetic markers that could predict the risk of statin-related muscle toxicity.
Main Methods:
- A case-control study design was employed with 263 samples.
- Genotyping was performed for 388 SNPs to identify associations with atorvastatin-induced muscle events.
- A discovery cohort was used to identify potential associations, followed by a validation cohort to confirm findings.
Main Results:
- The CYP2D6*4 allele was significantly associated with atorvastatin-induced muscle events in both discovery and validation cohorts (total P=0.001, odds ratio=2.5).
- The frequency of the CYP2D6*4 allele was approximately 50% in patients with atorvastatin-induced muscle events, compared to 28% in controls.
- A similar trend was observed for simvastatin-induced muscle events, suggesting a broader statin-wide association.
Conclusions:
- The CYP2D6*4 allele is associated with muscle-related adverse events caused by atorvastatin and potentially other statins.
- This genetic association may contribute to understanding statin-induced myopathy and inform risk assessment for patients.
- Pharmacogenetic insights into CYP2D6*4 could improve the safe and effective use of statin therapy.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...